Key result
Reclassifying pediatric cardiomyopathy into mechanism-specific rare diseases could provide an operational framework for targeted therapies and precision trials.
Reclassifying pediatric cardiomyopathy into mechanism-specific rare diseases may provide an operational framework to enable targeted therapies and precision clinical trials.
The greatest barrier to precision medicine in pediatric cardiomyopathy may no longer be biology but classification. Reclassifying cardiomyopathy into mechanism-specific rare diseases could provide an operational framework for targeted therapies and precision trials.
No takes yet. Share an insight, caveat, or question.
Briganti et al. (2026) studied this question. Reclassifying pediatric cardiomyopathy into mechanism-specific rare diseases could provide an operational framework for targeted therapies and precision trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: